证券代码：002022 证券简称：科华生物 公告编号：2023-088 债券代码：128124 债券简称：科华转债 经审议，监事会认为：董事会编制和审议公司《2023 年第三季度报告》的程 序符合有关法律、法规的规定，《2023 年第三季度报告》真实、准确、完整地反 映了报告期内公司的实际情况，所记载事项不存在任何虚假记载、误导性陈述或 者重大遗漏。 具体详见公司于 2023 年 10 月 28 日在《证券时报》、《中国证券报》、《上海 证券报》及巨潮资讯网（http://www.cninfo.com.cn）披露的《2023 年第三季度 报告》（公告编号：2023-086）。 上海科华生物工程股份有限公司 第九届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 上海科华生物工程股份有限公司（以下简称"公司"）第九届监事会第三次 会议（以下简称"本次会议"或"会议"）通知于2023年10月24日以邮件方式送 达各位监事，会议于2023年10月27日以通讯表决方式召开。本次会议由监事会主 席谢岚女士主持。本次会议应出 ...

Financial Performance - The company's revenue for Q3 2023 was ¥507,746,754.42, a decrease of 65.44% compared to the same period last year[5] - The net profit attributable to shareholders was -¥41,082,204.59, representing a decline of 122.01% year-on-year[5] - The basic earnings per share for the period was -¥0.0799, down 122.01% from the previous year[5] - Total operating revenue for the current period is CNY 1,904,222,528.93, a decrease from CNY 5,382,824,487.50 in the previous period, representing a decline of approximately 64.7%[17] - Net profit for the current period is CNY 48,569,569.90, a significant decrease from CNY 1,932,027,220.32 in the previous period, reflecting a decline of approximately 97.5%[19] - The company recorded a total comprehensive income of CNY 64,458,740.25, down from CNY 1,928,649,778.58 in the previous period, reflecting a decrease of approximately 96.7%[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,038,165,189.77, a decrease of 20.14% from the end of the previous year[5] - Total current assets amount to ¥4,571,937,062.51, a decrease from ¥6,445,298,850.16 at the beginning of the year[14] - Total non-current assets are reported at ¥2,466,228,127.26, compared to ¥2,367,858,163.16 at the start of the year[15] - Total current liabilities are ¥878,252,349.76, significantly lower than ¥2,053,128,583.43 at the beginning of the year[15] - Total liabilities stand at ¥1,813,253,376.66, compared to ¥2,961,151,839.11 previously[15] - The company has a total equity of ¥5,224,911,813.11 as of September 30, 2023[15] Cash Flow - Cash flow from operating activities showed a net outflow of -¥543,354,193.70, an increase in expenditure of 136.87% year-on-year[5] - The company reported a net cash flow from operating activities of CNY -543,354,193.70, compared to CNY 1,473,832,871.47 in the previous period, indicating a negative shift in cash flow[20] - The cash inflow from operating activities totaled CNY 2,110,280,610.29, a decrease from CNY 5,579,674,352.29 in the previous period, indicating a decline of about 62.2%[20] - In Q3 2023, the net cash flow from investment activities was -581,634,752.95 CNY, compared to -229,736,010.09 CNY in Q3 2022, indicating a significant increase in cash outflow[21] - The total cash outflow from financing activities reached 695,804,612.47 CNY in Q3 2023, up from 156,988,822.21 CNY in the same period last year, reflecting increased financial obligations[21] - The net cash flow from financing activities was -519,092,154.67 CNY in Q3 2023, contrasting with a positive cash flow of 45,404,973.78 CNY in Q3 2022, highlighting a shift in financing dynamics[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 49,939[11] - The largest shareholder, Zhuhai Baolian Investment, holds 18.64% of shares, totaling 95,863,038 shares, with 24,000,000 shares pledged[11] Expenses and Investments - Research and development expenses increased to CNY 186,166,801.41 from CNY 157,608,564.43, marking an increase of about 18.1%[17] - The company invested 184,000,000.00 CNY in capital expenditures during Q3 2023, indicating ongoing investment in fixed and intangible assets[21] - The company reported a significant increase in cash paid for dividends and interest, totaling 527,298,117.29 CNY in Q3 2023, compared to 69,290,664.65 CNY in Q3 2022[21] Accounting and Audit - The company has not undergone an audit for the Q3 2023 report, which may affect the perception of financial reliability[22] - The company is implementing new accounting standards starting in 2023, which may impact future financial reporting and analysis[22]

| 证券代码：002022 | 证券简称：科华生物 | | | --- | --- | --- | | 债券代码：128124 | 债券简称：科华转债 | 公告编号：2023-085 | 上海科华生物工程股份有限公司 关于 2023 年第三季度可转债转股情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： | 证券代码：002022 | | | | | | | | | | 证券简称：科华生物 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 债券代码：128124 | | | | | | | | | | 债券简称：科华转债 | | 转股价格：人民币 | 20.64 | | | | | | 元/股 | | | | | 转股期限：2021 | | | | | | | | | | | | | | | | | | | | | 27 | 日 | | 年 | 2 | 月 | 2026 | 年 | 7 | 3 | 日至 | 月 | | | 根据《深圳证券交易所股票 ...

上海科华生物工程股份有限公司 独立董事关于第九届董事会第三次会议相关事项 的独立意见 作为上海科华生物工程股份有限公司（以下简称"公司"）的独立董事，我们 依据《上市公司独立董事规则》、《深圳证券交易所股票上市规则》等法律、法规 和规范性文件及《上海科华生物工程股份有限公司章程》（以下简称"《公司章程》"） 的有关规定，就第九届董事会第三次会议相关事项发表如下独立意见： 一、关于聘任公司副总裁的独立意见 经审核，我们认为：公司本次拟聘任HYUK SHIN KANG（姜赫信）先生为公司 副总裁，其具备履行副总裁职责的任职条件和工作经验，任职资格符合《中华人 民共和国公司法》、《深圳证券交易所上市公司自律监管指引第1号——主板上市 公司规范运作》等法律法规、规范性文件及《公司章程》有关规定。本次聘任公 司副总裁的程序符合《中华人民共和国公司法》、《深圳证券交易所股票上市规则》 及《公司章程》的有关规定。因此，我们同意聘任HYUK SHIN KANG（姜赫信）先 生为公司副总裁，任期自董事会审议通过之日起至公司第九届董事会任期届满之 日止。 1 （本页无正文，系《上海科华生物工程股份有限公司独立董事关于第九届董事会 ...

关于产品获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，上海科华生物工程股份有限公司（以下简称"公司"）收到上海市药 品监督管理局颁发的《医疗器械注册证》（体外诊断试剂）。具体情况如下： | 证券代码：002022 | 证券简称：科华生物 | 公告编号：2023-084 | | --- | --- | --- | | 债券代码：128124 | 债券简称：科华转债 | | 上海科华生物工程股份有限公司 上海科华生物工程股份有限公司董事会 2023 年 8 月 26 日 以上新产品医疗器械注册证的取得，丰富了公司产品线，将对公司业务发展 具有正面影响。公司目前尚无法预测上述产品对公司未来营业收入的影响，敬请 投资者给予关注并注意投资风险。 特此公告。 | 序号 | 产品名称 | 注册证编号 | | | 注册证有效期 | | | | | 适用范围/预期用途 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 尿转铁蛋白测定试剂盒 | ...

特此公告。 上海科华生物工程股份有限公司董事会 2023 年 8 月 26 日 附件：个人简历 | 证券代码：002022 | 证券简称：科华生物 公告编号：2023-083 | | --- | --- | | 债券代码：128124 | 债券简称：科华转债 | 上海科华生物工程股份有限公司 关于聘任公司副总裁的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 上海科华生物工程股份有限公司（以下简称"公司"）于 2023 年 8 月 25 日 召开第九届董事会第三次会议，审议通过了《关于聘任公司副总裁的议案》，根 据公司实际情况及《中华人民共和国公司法》、《上海科华生物工程股份有限公司 章程》等规定，经公司总裁李明先生提名，董事会提名委员会审核通过，董事会 同意聘任 HYUK SHIN KANG（姜赫信）先生为公司副总裁（简历附后），任期自董 事会审议通过之日起至公司第九届董事会任期届满之日止。 公司独立董事对本次聘任副总裁的事项发表了同意的独立意见，具体详见公 司同日在指定信息披露网站巨潮资讯网（http://www.cninfo.com.cn）的相关公 ...

| 证券代码：002022 | 证券简称：科华生物 | 公告编号：2023-082 | | --- | --- | --- | | 债券代码：128124 | 债券简称：科华转债 | | 上海科华生物工程股份有限公司 第九届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 上海科华生物工程股份有限公司（以下简称"公司"）第九届董事会第三次 会议（以下简称"本次会议"或"会议"）通知于 2023 年 8 月 22 日以邮件方式 送达全体董事、监事、总裁及其他高级管理人员，会议于 2023 年 8 月 25 日以通 讯表决的方式召开。本次会议由公司董事长马志超先生主持。本次会议应参会董 事 5 人，实际参会董事 5 人（包含 2 名独立董事）。本次会议的召开符合《中华 人民共和国公司法》（以下简称"《公司法》"）、《上海科华生物工程股份有限公司 章程》（以下简称"《公司章程》"）和《上海科华生物工程股份有限公司董事会议 事规则》的有关规定。 二、董事会会议审议情况 （一）审议通过《关于聘任公司副总裁的议案》 根据公司 ...

证券代码：002022 证券简称：科华生物 债券代码：128124 债券简称：科华转债 上海科华生物工程股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------------|---------------------------|------------------------------------------------------------| | | | 编号：2023006 | | 投资者关系活动 | √特定对象调研 | 分析师会议 | | 类别 | □ 媒体采访 | 业绩说明会 | | | □ 新闻发布会 □ | 路演活动 | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及 | 西南证券 | 周海涛 | | 人员姓名 | 天风证券 李浩时 | | | 时间 | 2023 年 8 月 18 日上午 | | | 地点 | 公司会议室 | | | 上市公司接待人员姓名 | | | | | 1、公司怎么对待行业集采？ | | | | | 拥抱集采，优化供应链、降本增效。在中国体外诊断市场快 | | | | 速发展以及国家政策 ...

Financial Performance - The company's operating revenue for the first half of 2023 was CNY 1,396,475,774.51, representing a 54.66% increase compared to CNY 902,928,251.87 in the same period last year[22]. - The net profit attributable to shareholders of the listed company decreased by 54.50% to CNY 21,128,073.92 from CNY 46,430,948.61 year-on-year[22]. - Basic earnings per share dropped by 54.49% to CNY 0.0411 from CNY 0.0903 in the same period last year[22]. - The company reported a significant decrease of 84.63% in net profit after deducting non-recurring gains and losses, amounting to CNY 6,885,105.47 compared to CNY 44,781,944.58 in the previous year[22]. - The weighted average return on net assets was 0.44%, a decrease of 0.79 percentage points from 1.23% in the previous year[22]. - The net cash flow from operating activities was negative at CNY -592,060,407.58, a significant decline of 1,545.77% compared to CNY 40,951,115.03 in the previous year[22]. - The total assets at the end of the reporting period were CNY 7,457,864,308.88, down 15.38% from CNY 8,813,157,013.32 at the end of the previous year[22]. - The net assets attributable to shareholders decreased by 5.57% to CNY 4,546,506,357.22 from CNY 4,814,922,149.78 at the end of the previous year[22]. - The company reported a total of 8,650.36 million yuan in other lawsuits, with no adverse impact on normal operations[94]. - The company has not experienced any bankruptcy reorganization during the reporting period[92]. Market and Industry Insights - The global in vitro diagnostics (IVD) market size was $67.11 billion in 2019 and is expected to reach $91.09 billion by 2027, with a compound annual growth rate (CAGR) of 4.8% from 2020 to 2027[30]. - China's IVD market size grew from approximately RMB 42.75 billion in 2015 to about RMB 80.57 billion in 2019, with a CAGR of 17.2%[31]. - By 2030, China's IVD market is projected to reach RMB 288.15 billion, capturing 33.2% of the global market share[31]. - The IVD industry is expected to see increased demand due to aging population and rising healthcare needs, supported by government policies promoting the healthcare sector[33]. - The global IVD market is dominated by North America (over 40% market share), Western Europe (20%), and Japan (9%), collectively accounting for over 70% of the market[30]. - The Chinese IVD industry is in its early development stage but is rapidly evolving due to policy support, technological advancements, and growing market demand[31]. Product Development and R&D - The company has over 100 reagent and instrument products, covering more than 12,000 hospitals and over 500 disease control centers across China, and exports to over 100 countries[34]. - The company aims to enhance its influence and core competitiveness in the IVD market by expanding its product portfolio and leveraging its technological expertise[33]. - The company launched 6 new instruments and 27 new reagent products during the reporting period, focusing on automation, intelligence, and systematization in its product offerings[39]. - The company has over 100 ongoing research projects, continuously improving product quality and expanding product lines, including preoperative packages and upgraded products[41]. - Research and development investment increased significantly by 136.88% to ¥154,933,153.74, reflecting the company's commitment to enhancing its R&D capabilities[48]. - The company is actively engaged in research and development of new biochemical and clinical diagnostic reagents, aiming to enhance its competitive edge[183]. Financial Management and Strategy - The company plans not to distribute cash dividends or issue bonus shares[7]. - The company emphasizes supply chain security and cost reduction, focusing on domestic sourcing of core materials to enhance supply chain safety[41]. - The company’s procurement strategy leverages group-scale advantages to reduce costs and improve efficiency through supply chain integration[37]. - The production model for reagents follows a "sales-driven production" approach, aligning production schedules with actual sales data and market forecasts[38]. - The company has a commitment to invest RMB 82.5 million in the centralized procurement and regional testing center project, with 33.14% of the investment completed[66]. - The company has not reported any significant equity investments during the reporting period[59]. - The company has not made any changes to the use of raised funds or their intended purposes[64]. Compliance and Governance - The company has established a Quality Assurance Department and Regulatory Affairs Department to ensure timely product registration in domestic and international markets, effectively reducing registration risks[75]. - The company has received multiple certifications, including GMP and ISO13485, ensuring compliance with international quality standards[45]. - The company actively fulfills its information disclosure obligations and emphasizes accurate and timely communication with investors[85]. - The company has revised its governance structure and internal regulations to enhance internal control effectiveness and promote sustainable development[84]. - The company is committed to enhancing its compliance management system to mitigate risks associated with regulatory changes[73]. Shareholder and Equity Information - The total number of shares increased from 514,296,809 to 514,298,081, with an increase of 1,272 shares due to the conversion of convertible bonds[117]. - Major shareholder Zhuhai Baolian Investment Holding Co., Ltd. holds 18.64% of the shares, totaling 95,863,038 shares[122]. - The company has not reported any share repurchase progress during the reporting period[119]. - The report indicates that there were no changes in the number of shares held by significant shareholders during the reporting period[122]. - The company is subject to regulations regarding the transfer of shares by executives after their departure, limiting them to 25% of their holdings annually[118]. Future Outlook - The company plans to enhance its market presence and product offerings in the medical device sector, focusing on innovative solutions[183]. - Future guidance indicates a projected revenue growth of 10% for the full year 2023[174]. - The company plans to launch two new products in Q3 2023, aiming to capture an additional 5% market share[174]. - The company is exploring potential acquisitions to expand its market presence in Southeast Asia[174].

上海科华生物工程股份有限公司 对子公司提供财务资助管理制度 （2023 年 8 月修订） 第一章 总 则 第一条 为规范上海科华生物工程股份有限公司（以下简称"公司"）提供 财务资助行为，防范财务风险，确保公司稳健经营，根据《中华人民共和国公司 法》、《中华人民共和国证券法》、《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》以及《上海科华生物工程股份有限公司章程》 （以下简称"《公司章程》"）等规定，结合公司的实际情况，制定本制度。 第二条 本制度所称子公司为公司下属依法设立的、具有独立法人资格、合 并范围内的所有企业，具体包括： （一）公司独资设立的全资附属公司； （二）公司与其他投资人共同出资设立的，公司持有其 50%以上股权的公司， 包括公司直接持有或由二级/三级等全资附属公司直接持有其 50%以上股权的公 司； （三）公司（包括二级/三级等全资附属公司）与其他投资人共同出资设立 的，公司虽持有其股权比例低于 50%，但能够决定其董事会半数以上成员的企业； 本制度所称提供财务资助，指公司向合并报表范围内的全资子公司和控股子 公司有偿或者无偿提供资金、委托贷款等行为。无偿提供资金、 ...